'We are pleased with our strong start to the year, delivering solid first-quarter performance, and our fourth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA. Furthermore, all our business segments posted year-over-year revenue growth on both a reported and organic basis. I'm very proud of what our team has accomplished and we remain focused on continuing our momentum by advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive global growth,' said
'We are also pleased with other key developments for our business during the quarter, including the appeal decision in the
'We will continue to focus on the foundation we set across the enterprise to deliver results and improve the health of patients worldwide,' continued
Amiselimod (S1P modulator): once-daily oral treatment of mild to moderate ulcerative colitis
Positive top-line Phase 2 data results announced in
Selected for Podium Presentation at Digestive Disease Week 2024 Conference on
Met with the
Advancing plans for Phase 2 study for Crohn's disease
RED-C: prevention and delay of first episode of hepatic encephalopathy
Enrollment of the second global Phase 3 trial completed in
CABTREO: first triple combination product for the treatment of acne vulgaris
New Drug Submission was submitted to
Thermage FLX: uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin's surface
Thermage FLX and the TR-4 Return Pad approved by
Clear + Brilliant Touch: fractionated laser device for skin rejuvenation
Planned regulatory submissions on track for
Approved in
Next Generation Fraxel: fractionated laser device for skin resurfacing
FDA submission planned in Q2 2024 and approval could occur in the second half of 2024
Xifaxan Appeal Decision Reinforces the Company's Salix Growth Strategy
On
Contact:
Email: ir@bauschhealth.com
Tel: 877-281-6642
Email: Corporate.communications@bauschhealth.com
Tel: 908-541-3785
(C) 2024 Electronic News Publishing, source